European Economic AreaNorthern IrelandREACH

ECHA Opens Consultation On Four Substances For REACH Annex XIV

ECHA has opened a three-month consultation on adding four substances to the REACH Authorisation List, signalling potential future authorisation duties for wide-dispersive uses.

Dr Steven Brennan

2 min readAI-drafted, expert reviewed

Industrial chemical compliance consultation context

The European Chemicals Agency (ECHA) has opened a three-month public consultation on a draft recommendation to add four substances to the REACH Authorisation List (Annex XIV). If the substances are ultimately added to Annex XIV, certain uses in the EU may require an authorisation to continue.

The consultation was published on 2 February 2026 and runs until 2 May 2026, closing at 23:59 Helsinki time. ECHA notes that prioritisation relies mainly on registration dossier information on uses and volumes, and it encourages registrants to keep dossiers up to date.

Substances Under Consultation

ECHA’s consultation lists the following substances, each already identified on the Candidate List as substances of very high concern (SVHCs) on different hazard grounds:

  • Bumetrizole (UV-326) (EC 223-445-4, CAS 3896-11-5), identified as very persistent and very bioaccumulative (vPvB) under Article 57(e)
  • UV-329 (EC 221-573-5, CAS 3147-75-9), also identified as vPvB under Article 57(e)
  • Triphenyl phosphate (EC 204-112-2, CAS 115-86-6), identified under Article 57(f) due to endocrine-disrupting properties for the environment
  • 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one (EC 438-340-0, CAS 119344-86-4), identified under Article 57(c) as toxic for reproduction, Category 1B (H360Df)

Typical Uses And Why ECHA Prioritised Them

In ECHA’s draft background documentation, UV-326 and UV-329 are described as UV stabilisers used across plastics, rubber and resins, as well as in coatings, adhesives, sealants, lubricants, cleaning products and inks, and in a wide range of articles. Triphenyl phosphate is described as a flame retardant and plasticiser with uses in polymer formulations, adhesives and sealants, coatings and paints, and in a broad range of articles, including electrical and electronic equipment and textiles, with some reported uses in cosmetics and personal care. The photoinitiator is described as primarily used for UV inks and coatings in industrial and professional printing.

ECHA reports EU use volumes within the authorisation scope ranging from 100 to less than 10,000 tonnes per year, depending on the substance, with wide-dispersive industrial, professional and, for several substances, consumer and article uses.

What To Watch Next

ECHA indicates a standard approach to transitional arrangements in Annex XIV, with a latest application date around 18 to 24 months after inclusion and a sunset date 18 months later, while review periods or exemptions would be set later through authorisation decisions.

Questions about this change

Which substances are covered by ECHA’s Annex XIV consultation?

The consultation covers Bumetrizole (UV-326), UV-329, Triphenyl phosphate, and the photoinitiator 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one, each with published EC and CAS identifiers and consultation deadlines.

What should companies do during an Annex XIV consultation?

Registrants and downstream users should provide detailed information on uses, volumes, conditions of use and potential exemptions, and ensure registration dossiers are current. That input can influence prioritisation, transitional timelines and the design of any future Annex XIV entry.

Dr Steven Brennan

CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.

More from Dr Steven Brennan

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX